Company: PSTV
Filing Date: 2025-03-04
Form Type: 8-K
Source: 0001193125-25-045305
Chunk: 3

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-03-04
Form: 8-K
Item: Item 1.01
Chunk 3
---
 Purchasers agreed to consent to the Private Placement and eliminate the Financing Restrictions.

Registration Rights

In connection with the Securities Purchase Agreement, as amended, the Company entered into a registration rights agreement (the “ Registration Rights Agreement”), dated as the Closing Date, with the Purchasers, pursuant to which the Company agreed to prepare and file a registration statement with the U. S. Securities and Exchange Commission (the “ SEC”) covering the resale of the Private Placement Shares, Prefunded Warrant Shares and Common Warrant Shares (the “ Registration Statement”) no later April 4, 2025 (the “ Filing Due Date”), and to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than May 5, 2025 (the “ Effectiveness Due Date”). In addition, pursuant to the Registration Rights Agreement, the Company is required to use its reasonable best efforts to keep the Registration Statement continuously effective from the date on which the SEC declares the Registration Statement to be effective until such date that all Registrable Securities (as such term is defined in the Registration Rights Agreement) covered by the Registration Statement have been sold pursuant to a registration statement under the Securities Act of 1933, as amended (the “ Securities Act”), under Rule 144 as promulgated by the SEC under the Securities Act (“ Rule 144”), or otherwise shall have ceased to be Registrable Securities.

In the event that (i) the Company fails to file the Registration Statement by the Filing Due Date, (ii) the Company fails to file with the SEC a request for acceleration of the Registration Statement within 5 Trading Days (as such term is defined in the Registration Rights Agreement) of the date that the Company is notified by the SEC that such Registration Statement will not be “reviewed” or will not be subject to further review, (iii) the Registration Statement is not declared effective on or prior to the Effectiveness Due Date, (iv) after being declared effective, (A) the Registration Statement ceases to remain continuously effective as to all Registrable Securities for which it is required to be effective, or (B) the holders are not permitted to utilize the prospectus in the Registration Statement to sell Registrable Securities, other than certain allowed delays, or (v) an allowed delay exceeds beyond the length permitted for an allowed delay, then the Company has agreed (unless the Registrable Securities are freely tradable pursuant to Rule 144) to make payments to each Purchaser as liquidated damages in an amount equal to